The role of an anti-diabetic drug metformin in the treatment of endocrine tumors

: Incidence of endocrine cancers is rising every year. Over the last decade, evidence has accumulated that demonstrates the anti-cancer effects of an anti-diabetic drug - metformin - in endocrine malignancies. We performed a literature review utilizing the Pubmed, Medline and clinicaltrials.gov databases using the keyword "metformin" plus the following terms: "thyroid cancer," "thyroid nodules," "parathyroid," "hyperparathyroidism," "adrenal adenoma," "Cushing syndrome," "hyperaldosteronism," "adrenocortical cancer," "neuroendocrine tumor (NET)," "pancreatic NET (pNET)," "carcinoid," "pituitary adenoma," "pituitary neuroendocrine tumor (PitNET)", "prolactinoma," "pheochromocytoma/paraganglioma." We found 37 studies describing the preclinical and clinical role of metformin in endocrine tumors. The available epidemiological data shows an association between exposure of metformin and lower incidence of thyroid cancer and pNETs in diabetic patients. Metformin treatment has been associated with better response to cancer therapy in thyroid cancer and pNETs. Preclinical evidence suggests that the primary direct mechanisms of metformin action include inhibition of mitochondrial oxidative phosphorylation via inhibition of both mitochondrial complex I and mitochondrial glycerophosphate dehydrogenase, leading to metabolic stress. Decreased ATP production leads to an activation of a cellular energy sensor, AMPK, and subsequent downregulation of mTOR signaling pathway, which is associated with decreased cellular proliferation. We also describe several AMPK-independent mechanisms of metformin action, as well as the indirect mechanisms targeting insulin resistance. Overall, repositioning of metformin has emerged as a promising strategy for adjuvant therapy of endocrine tumors. The mechanisms of synergy between metformin and other anti-cancer agents need to be elucidated further to guide well-designed prospective trials on combination therapies in endocrine malignancies.